How big could the return be with CSL shares in 2024?

Could this biotech company be a market beater in 2024?

| More on:
Couple looking at their phone surprised, symbolising a bargain buy.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Limited (ASX: CSL) shares have been out of form in 2023.

As things stand, the biotechnology giant's shares are on course to record a decline of 7%.

But according to a note out of Citi, things could be very different next year, with the broker tipping some big returns for investors.

What is Citi saying about CSL shares?

Firstly, let's take a look at the note from last week and see what Citi is saying about the company.

According to the note, the broker attended the virtual Plasma-Derived Therapies investor event of rival Takeda.

Pleasingly, it came away from the event feeling very positive about immunoglobulin demand growth despite competition from FcRns. It explains:

We attended Takeda's virtual Plasma-Derived Therapies (PDT) investor event. Takeda is expecting mid-to-high single digit volume growth for Immunoglobulin (Ig) over the medium-term despite the competition from FcRns – this is in-line with CSL's expectations and our forecasts. Takeda anticipates the impact of anti-FcRn to be limited to <10% of total IG market.

Citi also highlights that Takeda's plan to expand its manufacturing capacity demonstrates its confidence in demand remaining very strong. It adds:

Takeda disclosed for the first time its plans to expand manufacturing capacity by 50% over the next 5 years, a sign of its positive outlook for Ig demand. Takeda PDT margins improved in 1H23 (numbers undisclosed) and are expected to be in-line with group level (OPM ~30%) over the "mid to long term".

But what about returns?

Citi has retained its buy rating and $325.00 price target on CSL's shares.

Based on its current share price of $266.92, this implies a potential upside of ~22% for investors over the next 12 months.

And with the broker expecting a ~1.5% dividend yield in FY 2024, the total return stretches to approximately 23.5%.

If Citi is on the money with its recommendations, a $10,000 investment would turn into approximately $12,350 in 2024.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A senior pharmacist talks to a customer at the counter in a shop
Healthcare Shares

Is it too late to buy Sigma shares to cash in on the Chemist Warehouse deal?

Can investors still make healthy returns with this stock?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

The best ASX 200 healthcare stocks to buy in 2025

These shares could give your portfolio a healthy boost next year according to Bell Potter.

Read more »

In the lab at work, the mature adult woman and young adult man smile as they review the results of their successful experimentation.
Healthcare Shares

ASX 300 healthcare stock lifts off on promising new results

Up 28% in a year, the ASX healthcare stock is leaping higher on Thursday.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

If you'd invested $5,000 in this ASX 300 healthcare stock a year ago, you'd now have $30,000!

This stock has made millions for investors over just a few months.

Read more »